Truist Financial
MRSN

Truist Financial’s Mersana Therapeutics MRSN Stock Holding History

Truist Financial’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-668
Closed -$104K – 2781
2021
Q4 		$104K Hold
668
– – ﹤0.01% 2675
2021
Q3 		$157K Hold
668
– – ﹤0.01% 2610
2021
Q2 		$227K Buy
668
+200
+43% +$75.7K ﹤0.01% 2533
2021
Q1 		$189K Hold
468
– – ﹤0.01% 2511
2020
Q4 		$311K Hold
468
– – ﹤0.01% 2133
2020
Q3 		$218K Buy
+468
New +$236K ﹤0.01% 2219

Other funds holding MRSN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Truist Financial's MRSN Position: Q1 2022 in Review

Truist Financial sold out of Mersana Therapeutics (MRSN) in Q1 2022, closing a stake of 668 shares — an estimated $104K sold.

Truist Financial first reported a position in MRSN in Q3 2020 and held it in 6 quarters. The position peaked at $311K in Q4 2020. 129 funds tracked by Wall St. Rank hold MRSN as of Q1 2022.

  • Truist Financial reported no remaining Mersana Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Truist Financial sold 668 Mersana Therapeutics shares in Q1 2022, an estimated $104K.
  • Truist Financial first reported a position in Mersana Therapeutics in Q3 2020 and held it in 6 quarters.
  • Truist Financial's Mersana Therapeutics position peaked at $311K in Q4 2020.
  • 129 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2022.

Based on Truist Financial's 13F filing for Q1 2022, filed 22 Apr 2022.